Once again catch-up Fu Enhua Pharmaceuticals Mida Zolun injection was approved through a consistent evaluation

According to NMPA's official website, Enhua Pharmaceuticals' Mida Zolun injection (4 acceptance numbers) was approved through the consistent evaluation, the product is a psychostational drug injection TOP2 varieties, People's Fu and Enhua in March and July 2019 respectively declared the consistency evaluation supplementary application, Enhua was the first approved to become the product's first evaluation enterprise.
Figure 1: Sales of Mida zolun injections Source: Minet China's public medical institutions terminal competition pattern Medazoleon injection adaptation is intramyal or intravenous for preoperative sedation/anti-anxiety/memory loss; intravenous injections for diagnosis, treatment, endoscopy (e.g. bronchial, gastroscopy, cystoscopy, coronary artery anthrasis, cardiac catheterization, Sedation/anti-anxiety/memory loss prior to or during tumor surgery, radiation procedures, succulent lacerations, and other individual medications or injunction with other central nervous system inhibitors; intravenous induction of whole hemp before administration of other anesthetics; and continuous intravenous drips of midazolam as an anesthetic for sedation in patients with tracheal intestion and mechanical flue gas, or for sedation in critical care. according to
meters of intranet data, in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal psychostational injection varieties TOP20, Midazolam ranked second, sales in 2019 more than 600 million yuan, the first half of 2020 leading enterprise Enhua market share remained at about 80%, the market share of Human Fu also reached 17.80%.
, according to Enhua Pharmaceuticals announcement data, the company for the product's first evaluation of enterprises, has invested about 3.61 million yuan in research and development costs.
table 1: Enhua Pharmaceuticals has been reviewed / the same review of neurological drug sources: Minet MED2.0 China Drug Review Database in recent years, Enhua Pharmaceuticals in the field of neurological drugs continue to make efforts in China's public medical institutions terminal enterprise ranking increased year by year, from TOP10 in 2018 to 2020H1 TOP5.
At present, Enhua Pharmaceuticals has reviewed / treated the same review of the nervous system drugs have reached 6, in the review of the approval of the consistency evaluation of supplementary applications related to products such as Shubili tablets, alipide tablets, injectable hydrochloric acid ryfentanyl tablets, chloronixine tablets and hydrochloric acid right metomycin injection.
source: NMPA official website, Minet database, company announcement